Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
308 studies found for:    akt cancer
Show Display Options
Rank Status Study
1 Recruiting AKT Inhibitor in Oestrogen Positive Breast Cancer
Condition: Invasive Breast Cancer
Intervention: Drug: AZD5363
2 Active, not recruiting
Has Results
Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
Conditions: Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
3 Completed
Has Results
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Conditions: Ovarian Sarcoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis
4 Suspended Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Conditions: Adult Solid Neoplasm;   Recurrent Colon Carcinoma;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Stage IIIC Colon Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Akt Inhibitor GSK2141795;   Drug: Dabrafenib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Trametinib
5 Completed Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206;   Drug: lapatinib ditosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
6 Recruiting Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer
Condition: Pancreatic Ductal Adenocarcinoma
Interventions: Biological: CD8+NKG2D+ AKT Cell;   Drug: Gemcitabine
7 Terminated Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IV Breast Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
Interventions: Drug: Akt inhibitor MK2206;   Biological: trastuzumab;   Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis
8 Active, not recruiting Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Conditions: Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unresectable Pancreatic Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Dinaciclib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
9 Active, not recruiting Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Conditions: Colon Mucinous Adenocarcinoma;   Colon Signet Ring Cell Adenocarcinoma;   Rectal Mucinous Adenocarcinoma;   Rectal Signet Ring Cell Adenocarcinoma;   Recurrent Colon Carcinoma;   Recurrent Rectal Carcinoma;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
10 Terminated Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis;   Drug: Lapatinib Ditosylate;   Other: Pharmacogenomic Study;   Other: Pharmacological Study
11 Active, not recruiting Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis
12 Active, not recruiting Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Conditions: Adult Solid Neoplasm;   Hormone-Resistant Prostate Cancer;   Recurrent Melanoma;   Recurrent Prostate Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Hydroxychloroquine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
13 Recruiting Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
14 Withdrawn Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Gallbladder;   Adenocarcinoma With Squamous Metaplasia of the Gallbladder;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Extrahepatic Bile Duct Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Stage II Gallbladder Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: selumetinib;   Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Procedure: quality-of-life assessment
15 Active, not recruiting MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Conditions: Adult Solid Neoplasm;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study
16 Active, not recruiting Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer
Condition: Breast Cancer
Interventions: Drug: ritonavir;   Procedure: therapeutic conventional surgery
17 Active, not recruiting Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Anastrozole;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Procedure: Neoadjuvant Therapy;   Other: Pharmacological Study;   Procedure: Therapeutic Conventional Surgery
18 Completed A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
Condition: Cancer
Interventions: Drug: GSK1120212;   Drug: GSK2110183
19 Completed An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer
Condition: Solid Tumours
Intervention: Drug: GSK2141795
20 Active, not recruiting Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Mixed Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Endometrial Undifferentiated Carcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.